Sleep intervention shows effects in human trials

The Claim

Sleep intervention shows effects in human trials

This conclusion is most relevant to: Adults (see study for details).

What the Research Shows

The conclusion draws on 8 linked studyies. Highlights from the cited literature:

• ▸Effects of Neiyanggong on cancer-related fatigue in breast cancer patients undergoing chemotherapy: a randomized controlled trial. (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026) — A randomized controlled trial of 72 breast cancer patients undergoing chemotherapy found that a staged progressive dynamic-static Neiyanggong intervention significantly reduced cancer-related fatigue (PFS-R total score interaction effect F=94.810, P<0.001, η²=0.807) and improved sleep quality (PSQI total score interaction effect Wald χ²=292.975, P<0.001) compared to routine care. After three chemotherapy cycles, fatigue scores were significantly lower in the Neiyanggong group (P<0.05), and notable improvements were seen in sleep latency, sleep efficiency, and daytime dysfunction (P<0.001).
• ▸ADDRESS-LC: study protocol for a phase 2, triple-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of bezisterim (NE3107) in adults with long COVID. (BMJ open, 2026) — This phase 2, triple-blind, placebo-controlled RCT will evaluate bezisterim (20 mg twice daily for 12 weeks) in 208 adults aged 18-69 with long COVID symptoms lasting at least 3 months. Outcomes include cognition, fatigue, sleep, post-exertional malaise, and quality of life measured via Cogstate Battery and PROMIS scales.
• ▸Effects of intranasal dexmedetomidine on postoperative sleep quality: a systematic review and meta-analysis of randomized controlled trials. (Frontiers in medicine, 2026) — Intranasal dexmedetomidine significantly improved subjective and objective postoperative sleep outcomes compared to placebo or other controls. Sleep efficiency and total sleep time increased, sleep latency reduced, and the risk of sleep disturbance decreased by 47% (RR=0.53).
• ▸Efficacy of open-label placebos for cardiac anxiety in inpatients with cardiovascular disease: A randomized controlled trial. (Journal of psychosomatic research, 2026) — In a randomized controlled trial of 122 inpatients with cardiovascular disease, open-label placebos (OLPs) added to treatment as usual and self-monitoring did not significantly improve cardiac anxiety, sleep quality, or well-being compared to control groups. All groups showed significant improvements over time, but no between-group differences were found for any primary outcome.

How It Works

The proposed biological pathway:

• ▸Intervention
• ▸Biological pathway
• ▸Sleep regulation
• ▸Outcome improvement

Who Might Benefit

Evidence fit by population:

• ▸Adults (see study for details)

Recommended Dose

See study

Limitations & Caveats

Important context when interpreting this evidence:

• ▸Sample size may be limited
• ▸Single study — more research needed
• ▸Population specificity may limit generalizability

Frequently Asked Questions